Dading, Latip .

HRN: 23-56-06  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/04/2024
CEFTAZIDIME 1GM (VIAL)
01/04/2024
01/10/2024
IV
1g
Q12
Nonhealing Wound
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueEye, Ear, Nose, Throat, & Mouth    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: